BioStem Technologies, Inc. (BSEM)
NASDAQ: BSEM · Real-Time Price · USD
3.680
+0.335 (10.01%)
At close: Aug 20, 2026, 4:00 PM EDT
3.770
+0.090 (2.44%)
After-hours: Aug 20, 2026, 4:50 PM EDT
BioStem Technologies Revenue
BioStem Technologies had revenue of $7.90M in the quarter ending June 30, 2026, a decrease of -27.95%. This brings the company's revenue in the last twelve months to $34.59M, down -49.13% year-over-year. In the year 2025, BioStem Technologies had annual revenue of $47.48M, down -31.84%.
Revenue (ttm)
$34.59M
Revenue Growth
-49.13%
P/S Ratio
1.73
Revenue / Employee
$473,789
Employees
73
Market Cap
65.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 47.48M | -22.18M | -31.84% |
| Dec 31, 2024 | 69.66M | 52.97M | 317.48% |
| Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
| Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
| Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apollomics | 8.84M |
| TScan Therapeutics | 7.11M |
| Immutep | 5.28M |
| Alps Group | 3.74M |
| RenovoRx | 1.98M |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 35.00K |
| eXoZymes | -700.00 |
BSEM News
- 1 day ago - BioStem Technologies Transcript: Micro-Cap Virtual Conference - Transcripts
- 1 day ago - BioStem Technologies Slides: Company presentation - Filings
- 8 days ago - BioStem Technologies Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - BioStem Technologies Quarterly report: Q2 2026 - Filings
- 8 days ago - BioStem Technologies Earnings release: Q2 2026 - Filings
- 5 weeks ago - BioStem files registration statement with SEC, to pursue Nasdaq listing - TheFly
- 6 weeks ago - BioStem Technologies issued four U.S. design patents for allograft technology - TheFly
- 6 weeks ago - BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies - Accesswire